AstraZeneca's Phase 3 Trial for Long-Acting Antibody Nirsevimab Meets Primary Endpoint
26 April 2021 - 8:47AM
Dow Jones News
By Matteo Castia
AstraZeneca PLC said Monday that the Phase 3 trial of its
Nirsevimab long-acting antibody met the primary endpoint.
The pharma giant said the endpoint for Nirsevimab consisted of
statistically significant reduction in the incidence of medically
attended lower respiratory tract infections caused by respiratory
syncytial virus.
Write to Matteo Castia at matteo.castia@dowjones.com
(END) Dow Jones Newswires
April 26, 2021 02:32 ET (06:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
Von Jul 2023 bis Jul 2024
